Evommune (EVMN) Return on Assets [ROA] (2025 - 2026)
Evommune (EVMN) reported Return on Assets [ROA] of -30.32% for Q2 2026, up 0.74 percentage points from the prior quarter.
Powered by 
Analysis
Evommune (EVMN) Return on Assets [ROA] (2025 - 2026) Analysis & Trends
For FY2025, Evommune posted Return on Assets [ROA] of -51.66%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 19.00% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 8.08% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 7.32% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 1.87% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 9.36% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 9.80% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | -7.67% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 2.00% |
| 10 | Evommune | 285.17 Mn | -352.34 Mn | - | -30.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -30.32% |
| Mar 31, 2026 | -31.06% |
| Dec 31, 2025 | -50.24% |
API Access
Evommune Return on Assets [ROA] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=EVMN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-assets-[roa]", "ticker": "EVMN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=EVMN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();